干扰素β-1α与干扰素β-1b治疗复发缓解型多发性硬化的成本效果分析

发布时间：2018-03-01 05:27

本文关键词： 复发缓解型多发性硬化干扰素β-α 干扰素β-b Markov模型成本效果分析　出处：《临床神经病学杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的探讨干扰素(IFN)β-1α与IFNβ-1b治疗复发缓解型多发性硬化(RRMS)的有效性及经济性。方法根据RRMS患者的残疾进展进程,利用扩展残疾状态量表评分(EDSS)评分,划分疾病进展过程中的不同状态。通过查阅文献获取各状态间的转移概率、各状态的健康效用值,应用药品价格估算各状态所花的费用。运用Markov模型分析法分析IFNβ-1α与IFNβ-1b治疗RRMS的成本效果。结果 IFNβ-1α组的累计成本及健康效果为169059.436$和7.913质量调整生命年(QALYs),成本效果比为21364.771$/QALY;IFNβ-1b组的累计成本及健康效果为212572.623$和7.912 QALYs,成本效果比为26867.116$/QALY。IFNβ-1α组的成本效果比低于IFNβ-1b组。结论 IFNβ-1α的成本效果比优于IFNβ-1b。因此选择IFNβ-1α作为延缓RRMS疾病进程的治疗药物,可获得更大的经济学效益。
[Abstract]:Objective to investigate the efficacy and economy of interferon interferon (IFN) 尾 -1 伪 and IFN 尾 -1b in the treatment of relapsed and remitting multiple sclerosis. Methods according to the progression of disability in patients with RRMS, the extended Disability status scale (EDSS) was used to evaluate the efficacy and economy of IFN-1 伪 and IFN 尾 -1b in the treatment of relapsed multiple sclerosis. Divide the different states in the progress of the disease. Get the transfer probability of each state by consulting the literature, the health utility value of each state, Markov model analysis was used to analyze the cost effect of IFN 尾 -1 伪 and IFN 尾 -1b in the treatment of RRMS. Results the cumulative cost and health effect of IFN 尾 -1 伪 group were 169059.436 $and 7.913 QAL-QALYS, with cost effect. The cumulative cost and health effect of IFN 尾 -1b group were 212572.623 $and 7.912 QALYS, and the cost-effectiveness ratio of IFN 尾 -1 伪 group was lower than that of IFN 尾 -1b group. Conclusion the cost effect ratio of IFN 尾 -1 伪 group is better than that of IFN 尾 -1b group. Greater economic benefits can be achieved.
【作者单位】：山西医科大学第一医院神经内科;
【基金】：山西省卫生厅科研课题(201301063)
【分类号】：R744.51

【相似文献】